Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
Status:
Completed
Trial end date:
2020-06-14
Target enrollment:
Participant gender:
Summary
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
infectious disease of the respiratory tract. Around 20% of those infected have severe
pneumonia and currently there is no specific or effective therapy to treat this disease.
Therapeutic options using malaria drugs chloroquine and hydroxychloroquine have shown
promising results in vitro and in vivo test. But those efforts have not involved large,
carefully-conducted controlled studies that would provide the global medical community the
proof that these drugs work on a significant scale. In this way, the present study will
evaluate the effectiveness and safety of the use of hydroxychloroquine combined with
azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with
pneumonia by SARS-CoV2 virus.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Israelita Albert Einstein
Collaborators:
Brazilian Research In Intensive Care Network EMS Hospital do Coracao Hospital Sirio-Libanes